Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 8 , ISSUE 1 ( January-June, 2019 ) > List of Articles

Original Article

Role of Bambuterol in the Management of Bronchial Asthma

Gurumit Singh, Sonal Kesar, Ambika Sambyal, Sunil Grover

Keywords : Asthma, bambuterol, pulmonary function tests, symptom score

Citation Information : Singh G, Kesar S, Sambyal A, Grover S. Role of Bambuterol in the Management of Bronchial Asthma. Indian J Respir Care 2019; 8 (1):27-30.

DOI: 10.4103/ijrc.ijrc_16_18

License: CC BY-NC-SA 4.0

Published Online: 05-12-2022

Copyright Statement:  Copyright © 2019; Indian Journal of Respiratory Care.


Background: Asthma is a long-term inflammatory disorder of the airways characterized by wheezing, dyspnea, and cough. For the last few decades, inhalational devices have been used in the management of the disease, but compliance remains the problem. Higher doses of oral medications used with prominent side effects precluded the use of oral beta-agonist bronchodilators, and the search for an ideal beta-adrenergic bronchodilator continues. This study was conducted for evaluation of the role of oral bambuterol in the management of bronchial asthma. Aims and Objectives: Our study aimed to evaluate the potency and effectiveness of oral bambuterol in the management of the disease in fifty patients followed up over 2 weeks with objective assessment of symptom scores and changes in the frequency of rescue bronchodilator after 2 weeks of treatment. Side effects, if any, were documented for all patients. Methods: The study was conducted on fifty patients with chronic bronchial asthma. They were given 10 mg of bambuterol once daily orally for 14 days. Pulmonary function tests were performed at days 1, 7, and 14. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peak expiratory flow rate (PEFR) were measured. Patients were assessed for symptom score and side effects at days 1, 7, and 14. Results: After completion of the study, significant improvement in the symptom score, FVC, FEV1, and PEFR was obtained with minimal side effects. Conclusion: Bambuterol 10 mg oral tablet once a day provides significant improvement in pulmonary function tests and effectively reduces asthmatic symptoms with minimal side effects.

  1. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350-62.
  2. Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of disease persistence and progression. Annu Rev Immunol 2004;22:789-815.
  3. Maddox L, Schwartz DA. The pathophysiology of asthma. Annu Rev Med 2002;53:477-98.
  4. Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: Comparison with salbutamol in adult asthmatic patients. Thorax 1988;43:674-8.
  5. Becker AB, Simons FE. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: Double-blind comparison with salbutamol and placebo in children with asthma. J Allergy Clin Immunol 1989;84:891-5.
  6. Svensson LA. Mechanism of action of bambuterol: A beta-agonist prodrug with sustained lung affinity. Agents Actions Suppl 1991;34:71-8.
  7. Chou YL, Wu CC, Wang HW. Effects of bambuterol and terbutaline on isolated rat's tracheal smooth muscle. Eur Arch Otorhinolaryngol 2010;267:1305-11.
  8. Krawiec ME, Jarjour NJ. Leukotriene receptor antagonists. Semin Respir Crit Care Med 2002;23:399-410.
  9. Sitar DS. Clinical pharmacokinetics of bambuterol. Clin Pharmacokinet 1996;31:246-56.
  10. Tunek A, Svensson LA. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. Drug Metab Dispos 1988;16:759-64.
  11. Tunek A, Levin E, Svensson LA. Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem Pharmacol 1988;37:3867-76.
  12. Persson G, Pahlm O. Efficacy and safety of bambuterol once daily in comparison with terbutaline tid. Clin Exp Allergy 1990;20 suppl 1:35.
  13. Van den Berg W, Alanko K, Sahlstrom K, Jarvinen M, Mikkola E, Jansson C, et al. Bambuterol once every evening in combination with terbutaline t.i.d. in asthmatic patients. Clin Exp Allergy 1990;20 suppl 1:35.
  14. Fugleholm AM, Ibsen TB, Laxmyr L, Svendsen UG. Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma. Eur Respir J 1993;6:1474-8.
  15. Nyberg L, Rosenborg J, Weibull E, Jönsson S, Kennedy BM, Nilsson M, et al. Pharmacokinetics of bambuterol in healthy subjects. Br J Clin Pharmacol 1998;45:471-8.
  16. Larsén K, Schmekel B. Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets. Eur J Clin Pharmacol 1993;45:303-5.
  17. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: NHLBI/WHO Workshop Report. Publication No. 02-3659. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002.
  18. Persson G, Baas A, Knight A, Larsen B, Olsson H. One month treatment with the once daily oral beta 2-agonist bambuterol in asthmatic patients. Eur Respir J 1995;8:34-9.
  19. Boskabady MH, Fasihfar M, Maemoori GA. Correlation between symptom score, wheeze, reversibility of pulmonary function tests and treatment response in asthma. Iran J Allergy Asthma Immunol 2003;2:61-7.
  20. Petrie GR, Chookang JY, Hassan WU, Morrison JF, O'Reilly JF, Pearson SB, et al. Bambuterol: Effective in nocturnal asthma. Respir Med 1993;87:581-5.
  21. Wig KL, Guleria JS, Bhasin RC, Holmes E, Vasudeva YL, Singh H. Certain clinical and epidemiological patterns of chronic obstructive lung disease as seen in Northern India. Indian J Chest Dis 1964;6:183-94
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.